Astrocytomas is of 55-60 % of primary intracranial tumors in adults. In most maximal safe surgical resection is associated with an improved prognosis. In some tumors, complete surgical resection may possible and curative. Adjuvant radiotherapy is a component of treatment for usually after a maximal safe surgical resection; irradiation is commonly started 2 to 4 weeks to allow for normal wound healing (Commonly a dose of 50-60 Gy in 25-30 fractions delivered over 5 to 6 weeks). Brachytherapy has been evaluated most thoroughly in malignant astrocytomas. In some cases chemotherapy is used as a adjuvant to irradiation or surgery. Nitrosoureas, vincristine, cisplatin and procarbazine may research therapeutic levels within the CNS. Only a limited number of agents are suitable for intrathecal injections: thiotepa, methotrexate and cytosine arabinoside (107-119).

This study retrospectively evaluates the astrocytomas cases who applied to our clinic between 1985-1997 years. 148 cases was astrocytomas. 76 were male and 72 were female (Male/Female: 1.05). The most common age range was 20-40 (5-76 ages). In 122 patients (82 %) the tumor had supratentorial, 22 patients the tumor had infratentorlal and 4 patients the tumor had medulla spinalis localization. 78 patients were at Grade I-II, 20 at Grade III, 50 at Grade IV. The most frequent surgery was total resection (60 patients, 41 %). 120 patients had total cranial, 28 had primer tumor side radiotherapy. The mean survival is 26 months.